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The blood concentration of intact proinsulin, but not total proinsulin, has been suggested to be a diagnos-
tic marker for type 2 diabetes mellitus (T2DM), but a sensitive assay speciﬁc for rodent intact proinsulin
is lacking. Here, a novel enzyme-linked immunosorbent assay (ELISA) for mouse intact proinsulin was
developed. The developed ELISA detected mouse intact proinsulin with the working range of 8.3 to
2700 pg/ml. Cross-reactivity with mouse split-32,33 proinsulin was approximately 100 times lower than
the reactivity with mouse intact proinsulin, and no cross-reactivity with mouse insulin was detected. The
developed ELISA was sufﬁciently sensitive to detect low levels of intact proinsulin in normal mouse
plasma. The measurement by the developed ELISA revealed that intact proinsulin was elevated in the
plasma of type 2 diabetic db/db mice as mice aged, and the ratio of intact proinsulin/insulin in plasma
was correlated with levels of glycated hemoglobin A1c as seen in T2DM patients. These results suggest
that the plasma level of intact proinsulin, but not total proinsulin, is a sensitive marker for pancreatic dys-
function and the ensuring diabetic disease progression of db/db mice. This ELISA could aid nonclinical
evaluation of therapeutic interventions in T2DM.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Proinsulin is the precursor molecule of insulin, a peptide hor-
mone that has a crucial role in the regulation of glucose metabo-
lism [1]. Proinsulin is synthesized in pancreatic b-cells and is
subsequently cleaved by two processing endopeptidases, prohor-
mone convertase (PC) 1/3 and PC2, to generate insulin and
C-peptide in the secretory granules of pancreatic b-cells [2]. In
the predominant processing pathway, proinsulin is ﬁrst cleaved
by PC1/3 at the peptide bond after R31–R32, which links the
B-chain of insulin to the C-peptide (B–C junction). The resulting
intermediate split-32,33 proinsulin is converted rapidly to
des-31,32 proinsulin by carboxypeptidase E (CPE), which removes
two C-terminal arginine residues [2–4]. To generate mature insu-
lin, des-31,32 proinsulin is subsequently cleaved by PC2 at the
peptide bond after K64–R65, which links the C-peptide to the
A-chain of insulin (C–A junction). The two C-terminal residuesK64–R65 of the C-peptide excised from the intermediate proin-
sulin can be removed by CPE digestion to generate the mature form
of C-peptide [2,3].
Patients with type 2 diabetes mellitus (T2DM) have exhibited
fasting hyperproinsulinemia in association with dysfunctional
pancreatic b-cells [5,6]. Impaired conversion of proinsulin to insu-
lin due to decreased PC1/3 activity in pancreatic b-cells has been
suggested to be associated with elevated levels of circulating intact
proinsulin as well as an increased ratio of intact proinsulin/insulin
or proinsulin/C-peptide in subjects with T2DM [7]. Thus, the circu-
lating level of intact proinsulin, but not total proinsulin, has been
considered to be an accurate marker for evaluation of altered func-
tion and/or mass of pancreatic b-cells (a characteristic of T2DM).
Several quantitative assays speciﬁc for intact proinsulin in humans
(i.e., ‘‘human intact proinsulin’’) have been developed [8].
However, assays for determination of intact proinsulin in rodents
(i.e., ‘‘rodent intact proinsulin’’) have not been developed so far.
We previously developed an ultrasensitive immunoassay for
rodent insulin using two anti-B-chain monoclonal antibodies:
Mab-13G4m1 and Mab-26B2m1 [9]. In this study, we developed
a highly sensitive immunoassay that could distinguish intact
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mediate in plasma) [10]. We generated monoclonal antibodies
speciﬁc to the uncleaved B–C junction of mouse/rat intact proin-
sulin and assessed the established antibodies for mouse intact
proinsulin enzyme-linked immunosorbent assay (ELISA) in combi-
nation with Mab-13G4m1. By using the newly developed
immunoassay, we ascertained whether plasma levels of intact
proinsulin or the ratio of intact proinsulin/insulin varies between
normal control mice and db/db mice that display many features
of T2DM such as hyperglycemia, insulin resistance, and obesity
[11].Materials and methods
Materials
Three synthetic peptides—13-mer peptide (SRREVEDPQVAQC),
11-mer peptide (REVEDPQVAQC), and 19-mer peptide
(EVEDPQVAQLELGGGPGAC), were obtained from Sigma–Aldrich
Japan (Tokyo, Japan) and used for mice immunization and a com-
petitive ELISA. Mouse intact proinsulin I and II were prepared by
our research team according to a method described previously
[12]. Split-32,33 proinsulin was also prepared in-house by cleavage
of the B–C junction of mouse intact proinsulin II with PC3
(MyBioSource, San Diego, CA, USA) and separation from remaining
intact proinsulin using reverse-phase high-performance liquid
chromatography. Identity and purity of split-32,33 proinsulin
(with no remaining intact proinsulin) was conﬁrmed by mass spec-
troscopy. The molecular weight of the split-32,33 proinsulin is
18 Da larger than that of intact proinsulin because of hydrolysis
at the 32–33 peptide bond. We could easily distinguish intact
proinsulin from its split form hydrolyzed at the B–C junction by
liquid chromatography/mass spectrometry analysis. Human proin-
sulin was purchased from R&D Systems (Minneapolis, MN, USA).
Synthetic 13-mer peptide was conjugated to maleimide-activated
keyhole limpet hemocyanin (KLH; Thermo Scientiﬁc, Waltham,
MA, USA) as the immunogen. Unless speciﬁed otherwise, all chem-
icals were purchased from Sigma–Aldrich Japan.
Ethics statement
All animal experiments were conducted in compliance with
protocols approved by the institutional animal care and use com-
mittee of Shionogi & Company (Osaka, Japan).
Establishment of anti-mouse intact proinsulin monoclonal antibodies
Anti-mouse intact proinsulin monoclonal antibodies were
established according to a method described previously [13].
Brieﬂy, 4- to 6-week-old female Balb/c mice (CLEA Japan, Tokyo,
Japan) were injected via the intraperitoneal route with 0.1 mg of
KLH-conjugated synthetic 13-mer peptide emulsiﬁed in complete
Freund’s adjuvant (Difco/Becton Dickinson, Franklin Lakes, NJ,
USA). Four additional injections of 0.1 mg of KLH-conjugated pep-
tide emulsiﬁed in incomplete Freund’s adjuvant were followed at
3-week intervals. Eight days after the ﬁfth immunization, mice
were boosted with 100 lg of adjuvant-free antigen. Three days
after the ﬁnal injection, splenocytes from immunized mice were
collected aseptically and fused to murine myeloma P3U1 cells
using 50% (w/v) polyethylene glycol (PEG) 4000. Hybridomas were
selected in hypoxanthine/aminopterin/thymidine medium. Ten
days later, culture supernatants of hybridoma cells were screened
as described below. A 384-well MaxiSorp plate (Nunc/Thermo
Scientiﬁc) was coated with goat anti-mouse immunoglobulin G(IgG; Shibayagi, Shibukawa, Japan) and blocked with 1% (w/v)
BlockAce (Dainippon Pharmaceuticals, Osaka, Japan). Then, culture
supernatants were added to individual wells and incubated with
biotinylated synthetic 13-mer peptide or intact proinsulin II and
streptavidin-conjugated horseradish peroxidase (streptavidin–
HRP; Thermo Scientiﬁc) overnight at 4 C. Wells were washed with
phosphate-buffered saline supplemented with 0.05% (w/v) Tween
20 (PBST). Then, tetramethylbenzidine (TMB; Dako, Tokyo, Japan)
substrate solution was added for the colorimetric assay. Cells in
positive wells were cloned twice by limiting dilution. The class
and subclass of immunoglobulin were determined using a Mouse
Immunoglobulin Isotyping ELISA Kit (Becton Dickinson) according
to the manufacturer’s instructions. The best hybridoma selected on
the basis of the reactivity and speciﬁcity for intact proinsulin was
cultured using a Wheaton CELLine Bioreactor Flask (AR Brown,
Osaka, Japan). The monoclonal antibody was puriﬁed from the cul-
ture supernatant using Protein G HP (GE Healthcare, Piscataway,
NJ, USA).
Evaluation of speciﬁcity of established antibodies for mouse intact
proinsulin by a competitive ELISA
Reactivity of established antibodies with mouse intact proin-
sulin I, mouse intact proinsulin II, or each of three synthetic
peptides (13-mer, 11-mer, and 19-mer) was evaluated by a com-
petitive ELISA with biotinylated mouse intact proinsulin II, which
was prepared with NHS–PEG4–Biotin (Thermo Scientiﬁc) accord-
ing to the manufacturer’s instructions. A 96-well MaxiSorp plate
(Nunc/Thermo Fisher, Rochester, NY, USA) was coated with
anti-mouse IgG overnight at 4 C and then blocked with 1% (w/v)
BlockAce for 2 h at room temperature. After washing three times
with PBST, 50 ll of antibody solution, 50 ll of the mixture of
biotinylated mouse intact proinsulin II (5 ng/ml) with strepta-
vidin–HRP (200 ng/ml), and 50 ll of reaction buffer containing
graded concentrations of mouse intact proinsulin or three syn-
thetic peptides (13-mer, 11-mer, and 19-mer) were placed into
each well of the plate. After incubation at 4 C overnight, the plate
was washed 3 times with PBST, and 100 ll of TMB (Dako, Glostrup,
Denmark) substrate solution was added to each well to initiate the
colorimetric reaction. The reaction was stopped by the addition of
0.5 N sulfuric acid. Then, optical absorbance was measured at
450 nm using an Envision 2102 Multilabel Reader (PerkinElmer,
Waltham, MA, USA).
Evaluation of binding afﬁnity of anti-mouse intact proinsulin
monoclonal antibody by surface plasmon resonance
The binding afﬁnity of the established monoclonal antibody for
recombinant mouse intact proinsulin was analyzed using a BIAcore
T200 Processing Unit (GE Healthcare). Goat anti-mouse IgG anti-
body was immobilized on a CM5 chip using an Amine Coupling
Kit (GE Healthcare). Anti-mouse intact proinsulin antibody was
captured by the immobilized anti-mouse IgG on the chip. Six
graded concentrations of mouse intact proinsulin II (160, 80, 40,
20, 10, and 0 nM) were injected into running buffer (10 mM
HBS–EP containing 0.01 M Hepes, 0.15 M NaCl, 3 mM ethylenedi-
aminetetraacetic acid, and 0.005% (w/v) surfactant P20, pH 7.4)
(GE Healthcare) at 30 ll/min and 25 C for more than 3 min (asso-
ciation phase). Chips were then washed for more than 1.5 h (disso-
ciation phase). For serial measurements, the sensor chip was
regenerated by quickly injecting Gly–HCl (pH 1.7) after each mea-
surement. Double-referencing was applied to eliminate responses
from the reference surface and buffer-only control. Afﬁnity was
determined as the equilibrium dissociation constant (KD) by simul-
taneously ﬁtting the association and dissociation phases of the
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Langmuir model on BIAevaluate version 1.0 (GE Healthcare).
Development of a sandwich ELISA speciﬁc for mouse intact proinsulin
The best antibody selected on the basis of the reactivity and
speciﬁcity for intact proinsulin was used for developing a sandwich
ELISA for mouse intact proinsulin in combination with
Mab-13G4m1, which was a monoclonal anti-rodent insulin
B-chain antibody established in our previous work [9].
A 96-well MaxiSorp white plate was coated with the selected
anti-mouse intact proinsulin B–C junction monoclonal antibody
(5 lg/ml) overnight at 4 C and blocked with 2% BlockAce for 2 h
at room temperature. After washing the plate twice with PBST,
10 ll of samples or standard solution of mouse intact proinsulin I
or II (3.7–2700 pg/ml) diluted with dilution buffer (100 mM NaCl,
1 mM MgCl2, 0.1 M ZnCl2, 0.01% [w/v] Tween 80, 1% [w/v] bovine
serum albumin, 0.05% [w/v] NaN3, and 50 mM Tris–HCl, pH 7.5)
and 40 ll of alkaline phosphatase (ALP)-labeled Mab-13G4m1
Fab solution (0.25 lg/ml in the dilution buffer) were added and
incubated overnight at 4 C. After washing 4 times with PBST, the
chemiluminescence reaction was initiated by the addition of
100 ll of ready-to-use CDP-Star with Emerald II (Roche
Diagnostics, Basel, Switzerland). Then, 20 min later, the chemilu-
minescence of each well was measured by an ARVO SX
Microplate Reader (PerkinElmer).
Validation of the ELISA for quantitative detection of intact proinsulin
in mouse plasma
Chemiluminescence of the buffer control (the dilution buffer)
was measured 20 times to provide a baseline concentration. In
addition, the lower limit of detection was deﬁned as the
mean + 2  standard deviation (SD) of the baseline value. Then,
serial dilution series (3.7, 11.1, 33.3, 100, 300, 900, and
2700 pg/ml) of recombinant mouse intact proinsulin II were mea-
sured as reference standard, and the assay range where the mea-
surement result showed good dilutional linearity was deﬁned.
The standard curve using recombinant mouse intact proinsulin I
was also deﬁned in the same way as mouse intact proinsulin II
described above. The cross-reactivity with recombinant mouse
split-32,33 proinsulin II (1000, 3000, 9000, 27,000, 81,000, and
243,000 pg/ml) or recombinant mouse insulin (300, 1000, 3000,
9000, 27,000, 81,000, and 243,000 pg/ml) was assessed and com-
pared with the result of the reference standard (standard curve).
Blood samples were collected from the thoracic aortas of male
8-week-old C57BL/6J nonfasted mice (CLEA Japan) and male
9-week-old db/db mice (Charles River Japan, Tokyo, Japan) using
a heparinized syringe under isoﬂurane anesthesia. Plasma was sep-
arated by centrifugation at 2000g for 15 min at 4 C and stored at
80 C until used for validation of the ELISA. Here, 50 ll of the
assay comprised 40 ll of ALP-Mab-13B4m1 Fab solution and
10 ll of plasma or its diluted sample with the dilution buffer.
Linearity of the ELISA was evaluated by measuring eight plasma
samples (four plasma samples each from normal mice and db/db
mice) and their 2-fold serial dilution series (1, 1/2, 1/4, and 1/8,
v/v) containing 10, 5, 2.5, and 1.25 ll of plasma, respectively.
Recovery of the ELISA was assessed as the ratio of actual mea-
surements to the ideal concentrations of spiked samples. Seven
concentrations (3.7, 11.1, 33.3, 100, 300, 900, and 2700 pg/ml) of
mouse intact proinsulin II standard protein were spiked into
10 ll of a mouse plasma sample and measured by the developed
ELISA in duplicate.
Reproducibility of the ELISA was veriﬁed by the intra- and
inter-assay precision assessment. Three mouse plasma samples
were assayed in eight replicates within a plate (intra-assay), andthen the same set of samples were assayed in eight replicates
across 10 plates over multiple days (inter-assay). The coefﬁcient
of variation (CV) was calculated for intra-assay precision and for
inter-assay precision.Determination of intact proinsulin in db/db mice and their normal
control littermates
To ascertain whether plasma levels of intact proinsulin vary
during development of T2DM-like phenotypes, 6-, 8-, and
9-week-old male db/db mice (Charles River Japan, Tokyo, Japan)
were fasted for 4 h, and then blood samples were collected from
the tail vein using a heparinized syringe under isoﬂurane anesthe-
sia. Normal control plasma was obtained from 6-week-old, lean,
control littermate m/m mice (Charles River Japan). Each group
comprised 10 mice. Blood samples were centrifuged at 2000g for
15 min at 4 C, and plasma fractions were collected and subjected
to determination of levels of total proinsulin, intact proinsulin,
insulin, and glucose. An aliquot of the residual pellet of blood cells
was collected for determination of levels of glycated hemoglobin
A1c (HbA1c). Plasma levels of glucose and HbA1c were measured
by an Automatic Analyzer (7180; Hitachi, Tokyo, Japan) using com-
mercial reagents (Sekisui Medical, Tokyo, Japan). Plasma levels of
total proinsulin were measured with a commercially available
Rat/Mouse Proinsulin ELISA (Mercodia, Uppsala, Sweden). Plasma
levels of intact proinsulin were measured by the developed ELISA
as described above. Plasma levels of insulin were measured with
the previously developed immunoassay system (intra- and
inter-assay CV values of <2.9% and <3.3%, respectively) [9]. Data
were expressed as the means ± SDs. Differences between groups
were analyzed by one-way analysis of variance followed by
Tukey’s test. The correlation between the values of HbA1c and the
ratio of total proinsulin/insulin or intact proinsulin/insulin was
analyzed by Pearson’s correlation coefﬁcient. Statistical signiﬁ-
cance was deﬁned as P < 0.05.Results
Establishment of hybridomas producing anti-mouse intact proinsulin
antibodies
Peptide immunogen was designed on the basis of the following
criteria; (i) it contains the cleavage site and its adjacent amino acid
sequence of the B–C junction; (ii) the amino-acid sequence is con-
served between mouse and rat; and (iii) the amino acid sequence is
conserved between proinsulin I and proinsulin II, which are nonal-
lelic gene products in rodents [14].
The 10-mer sequence (SRREVEDPQV) satisﬁed the criteria
mentioned above, but it was slightly short to be an effective
immunogen (Fig. 1B). We synthesized the 13-mer peptide
(SRREVEDPQVAQC) of proinsulin II as the immunogen, which had
the common 10-mer sequence, two amino acids extending from
its C-terminal end, and a Cys for conjugation with KLH.
Generating high-afﬁnity antibodies against mouse antigens is
generally difﬁcult in mice immunized with autoantigen, but only
a few mice immunized with KLH-conjugated 13-mer peptide
showed increased reactivity with mouse intact proinsulin. Spleen
cells collected from the immunized mice were fused to mouse
myeloma cells, and then we selected the hybridoma clone 9F5,
whose antibody showed high reactivity with the recombinant
mouse intact proinsulin, low cross-reactivity with the split-32,33
proinsulin, and good response in combination with Mab-13B4m1.
The subclass of the antibody Mab-9F5 was determined to be
IgG1/j using an immunoglobulin isotyping ELISA.
BA
Fig.1. Structure of proinsulin and its amino acid sequences surrounding the B–C junction. (A) Proinsulin is an 86-residue-long single polypeptide having three intramolecular
disulﬁde bonds. It is processed by proteolytic cleavage at the B–C junction (32R–33E) and C–A junction (65R–66G) to generate C-peptide and insulin, which comprises two
polypeptide chains (A-chain and B-chain), linked by two disulﬁde bonds. (B) Amino acid sequences surround the B–C junction of the proinsulin molecules, proinsulin I and
proinsulin II, in mice and rats.
Fig.2. Speciﬁcity of the established monoclonal antibody Mab-9F5 for mouse intact
proinsulin as assessed by analyses of competitive inhibition. Mab-9F5 was
incubated with biotinylated mouse intact proinsulin II in the presence or absence
of the indicated concentrations of unlabeled mouse intact proinsulin II (), 13-mer
peptide (h), 11-mer peptide (N) or 19-mer peptide () overnight at 4 C. Binding
activity is shown by the relative percentage to maximum binding in the absence of
competitors.
Table 1
Afﬁnity analysis of the established antibody Mab-9F5.
Clone ka (1/Ms) kd (1/s) KD (M)
9F5 4.7  105 9.1  10–4 1.9  10–9
Note: ka, association rate constant; kd, dissociation rate constant; KD, equilibrium
dissociation constant.
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To characterize the established monoclonal antibody Mab-9F5,
speciﬁcity and afﬁnity were examined by a competitive ELISA
and surface plasmon resonance (SPR). In the competitive ELISA,
the addition of increasing amounts of mouse intact proinsulin II
or the 13-mer peptide, both of which have two arginine residues
of the B–C junction, inhibited the speciﬁc binding of Mab-9F5 to
biotinylated intact proinsulin II, with half-maximal inhibitory con-
centration (IC50) values of 1.6 or 6.0 nM, respectively (Fig. 2). The
11-mer or 19-mer peptide, which lacks the arginine residues of
the B–C junction, showed no inhibitory effect on the binding of
Mab-9F5 and biotinylated intact proinsulin II (Fig. 2). In the SPR
analysis using a BIAcore T200 system, the binding afﬁnity (KD) of
the Mab-9F5 against mouse intact proinsulin II was determined
to be 1.9 nM (17.1 pg/ml) (Table 1).
Development of a sandwich ELISA for mouse intact proinsulin
To develop a novel sandwich ELISA for determination of the
concentration of mouse intact proinsulin, Mab-9F5 (capture anti-
body) and ALP-labeled Mab-13G4m1 Fab (detection antibody)
were used. The lower detection limit was determined to be
3.7 pg/ml as the baseline + 2  SD deﬁned by measuring buffer
control (n = 20). The standard curve of mouse intact proinsulin II
had good dilutional linearity in the range of 3.7 to 2700 pg/ml
and completely coincided with that of mouse intact proinsulin I
(Fig. 3A). Intra-assay CV (n = 3) was 0.5 to 5.9% for mouse intact
proinsulin II or 0.3 to 5.2% for mouse intact proinsulin I.
Reactivity with split-32,33 proinsulin was approximately
100 times lower than that with intact proinsulin, and no reactivity
with mouse insulin was observed (Fig. 3B).
Validation of the newly developed ELISA for quantiﬁcation of intact
proinsulin in mouse plasma
First, we evaluated the dilutional linearity of the measurement
of plasma levels of intact proinsulin using the developed ELISA.
Measurement of the 2-fold serial dilutions (1, 1/2, 1/4, and 1/8,
v/v) of four C57BL/6J mice plasma samples and four db/db mice
plasma samples displayed good linearity (Fig. 4). Because
high-dose db/db mice plasma samples also displayed goodlinearity, the high-dose hook effect was excluded from these sam-
ples. The result suggested that no factors in normal mouse or db/db
mouse plasma interfered with the developed ELISA as long as
plasma was used at 20% or less.
To further evaluate the analytical recovery of mouse intact
proinsulin spiked into mouse plasma, the lowest dose sample
(9.2 ± 0.4 pg/ml of endogenous mouse intact proinsulin) was
selected from 10 C57BL/6 mouse plasma samples and spiked with
AB
Fig.3. Concentration–chemiluminescence plots for the developed ELISA. (A) Standard curve of mouse intact proinsulin II (s) and mouse intact proinsulin I () using the
developed ELISA. Intra-assay CV (n = 3) was 0.5 to 5.9% for mouse intact proinsulin II or 0.3 to 5.2% for mouse intact proinsulin I. (B) Cross-reactivity with split-32,33
proinsulin (h) and with mouse insulin (N) were assessed using the developed ELISA and compared with the standard curve of mouse intact proinsulin II (s).
Chemiluminescence is shown by the mean value of triplicate measurements.
Fig.4. Linearity of the developed ELISA for intact proinsulin in serially diluted
mouse plasma. Blood samples were collected from four normal C57BL/6J mice and
four db/db mice in the nonfasted state. The eight plasma samples were serially
diluted as indicated for determination by the developed ELISA. Each point
represents the mean value of duplicate measurements.
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33.3, 100, 300, 900, or 2700 pg/ml). The spiked samples were sub-
jected to measurement by the developed ELISA (Table 2). Therecovery ratio at all seven concentrations ranged from 95.3 to
105.2%, with excellent CV values (<6.7%), suggesting that the assay
showed good precision in the range of 3.7 to 2700 pg/ml even in
the presence of 20% mouse plasma.
To evaluate the reproducibility of the assay, three mouse
plasma samples, which contained the lowest, medium, and highest
levels of intact proinsulin we had measured, were measured by the
developed ELISA in eight replicates, and this assay was repeated
across 10 plates over multiple days. The results shown in Table 3
demonstrated that intra- and inter-assay CV values were 0.7 to
3.0% (n = 8) and 2.0 to 4.0% (n = 10), respectively, suggesting good
reproducibility of the assay (Table 3).
Determination of intact proinsulin in mouse plasma using the
developed ELISA
The ratio of intact proinsulin/insulin in plasma is used as a diag-
nostic marker of dysfunction of pancreatic b-cells in T2DM [8]. To
ascertain whether an elevated ratio of intact proinsulin/insulin in
plasma is associated with hyperglycemia in type 2 diabetic db/db
mice as seen in T2DM patients, plasma concentrations of total
proinsulin, intact proinsulin, and insulin were measured in db/db
mice and normal control m/m mice. Besides body weight and
blood glucose, blood levels of HbA1c, a pivotal biomarker reﬂecting
Table 2
Recovery of intact proinsulin from spiked mouse plasma samples.
Spiked concentration
(pg/ml)
Measured concentrationa
(pg/ml)
Recoveryb
(%)
CV
(%)
0 9.2 ± 0.4 4.8
3.7 12.7 ± 6.7 105.2 ± 25.8 6.7
11.1 20.4 ± 2.9 100.6 ± 5.4 2.9
33.3 42.9 ± 3.5 101.3 ± 4.5 3.5
100 109.4 ± 2.5 100.2 ± 2.7 2.5
300 295.2 ± 10.7 95.3 ± 3.6 3.6
900 919.1 ± 22.0 101.1 ± 2.5 2.4
2700 2738.1 ± 122.7 101.1 ± 4.5 4.5
a Mean ± standard deviation of six measurements.
b Recovery (%) = (measured concentration  endogenous concentration)/spiked
concentration  100. The endogenous concentration is the measured concentration
of the unspiked sample.
Table 3
Reproducibility of the developed ELISA for measurement of plasma intact proinsulin.
Intra-assay (n = 8) Inter-assay (n = 10)
Mean ± SD (pg/ml) CV (%) Mean ± SD (pg/ml) CV (%)
Plasma 1 8.2 ± 0.2 3.0 8.3 ± 0.3 4.0
Plasma 2 473.7 ± 3.2 0.7 467.2 ± 9.4 2.0
Plasma 3 1269.0 ± 17.5 1.4 1250.6 ± 31.0 2.5
Table 4
Characteristics of type 2 diabetic db/db mice and normal control m/m mice.
Parameter m/m mice
6 W
db/db mice
6 W 8W 9W
Body weight (g) 21 ± 2 30 ± 2** 34 ± 2**, 41 ± 5**,
HbA1c (%) 3.1 ± 0.1 3.4 ± 0.3 4.6 ± 0.5**, 6.1 ± 0.8**,
Plasma glucose
(mg/dl)
226 ± 25 410 ± 133** 486 ± 114**, 559 ± 103**,
Plasma insulin
(ng/ml)
0.4 ± 0.1 10.4 ± 2.5** 9.3 ± 2.4** 7.6 ± 3.2**,
Note: Data are the means ± SDs of 10 animals.
P < 0.05, P < 0.01 versus 6-week-old db/db mice.
** P < 0.01 versus normal control m/m mice.
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sured as the index of hyperglycemia.
As shown in Table 4, younger db/db mice at 6 weeks of age
showed signiﬁcantly higher levels of body weight, plasma glucose,
and plasma insulin, but not blood HbA1c, compared with those of
age-matched normal control mice. In addition, as db/db mice aged
and body weight was increased, the levels of HbA1c and plasma glu-
cose increased signiﬁcantly, but plasma insulin declined, indicating
an age-dependent worsening of hyperglycemia in db/db mice.
Plasma total proinsulin levels in db/db mice were more than 30
times higher than those of normal mice (103 ± 38 pg/ml) but did
not increase any more even in db/db mice at 9 weeks of age
(Fig. 5A). On the other hand, plasma levels of intact proinsulin in
db/db mice at 6 weeks of age were more than 20 times higher than
those in normal control mice (19 ± 8 pg/ml) and progressively
increased as mice aged by 9 weeks of age (Fig. 5B). Although the
ratio of intact proinsulin/insulin in plasma of db/db mice at
6 weeks of age was comparable to that of age-matched normal
control mice, the ratio signiﬁcantly increased as db/db mice aged
by 9 weeks of age (Fig. 5C). The ratio of intact proinsulin, but not
total proinsulin, to insulin in plasma was signiﬁcantly correlated
with blood HbA1c level (r = 0.85, P < 0.0001), suggesting that dys-
function of pancreatic b-cells was associated with the deterioration
of glycemic control (Fig. 5D).Discussion
Determination of circulating levels of intact proinsulin has been
shown to be an attractive strategy to monitor the degree of
dysfunction of pancreatic b-cells due to chronic hyperglycemia
[5–7]. In the current study, we established a novel monoclonal
antibody (Mab-9F5) speciﬁc for the uncleaved B–C junction of
mouse intact proinsulin and developed a sandwich ELISA for sensi-
tive determination of intact proinsulin in mouse plasma. The
developed ELISA revealed that plasma levels of intact proinsulin
were elevated in db/db mice and that the ratio of intact
proinsulin/insulin in plasma was positively correlated with blood
HbA1c levels.
Proinsulin processing comprises primary proteolytic cleavage at
the B–C junction to generate des-31,32 proinsulin intermediate
and secondary cleavage at the C–A junction to yield insulin and
C-peptide [2–4]. Split-32,33 proinsulin is the major proinsulin
intermediate present in plasma [10]. Hence, the monoclonal anti-
body speciﬁc for the uncleaved B–C junction is the most important
component of the ELISA for mouse intact proinsulin. In mice and
rats, amino acid sequences surrounding the B–C junction are highly
conserved among mouse/rat proinsulin molecules and their sub-
types (proinsulin I and proinsulin II) coded by two nonallelic genes
[14] (Fig. 1). To establish a monoclonal antibody speciﬁc for mouse
intact proinsulin, we synthesized the 13-mer peptide of the
sequence surrounding the B–C junction as an immunogen. The
13-mer peptide raised a high titer of antisera against the immuno-
gen peptide in all 10 Balb/c mice, but 9 antisera showed weak reac-
tivity with mouse intact proinsulin owing to immune tolerance
against the self-antigen. Because only 1 mouse produced a high
titer of antibody against mouse intact proinsulin besides the
13-mer peptide, splenocytes were collected and subjected to
hybridoma generation. Hybridomas were screened based on the
sensitivity and speciﬁcity for mouse intact proinsulin.
Speciﬁcity of the developed anti-mouse intact proinsulin mon-
oclonal antibody Mab-9F5 was assessed by a competitive ELISA.
Mab-9F5 reacted with the uncleaved B–C junction with high afﬁn-
ity (IC50 = 1.6 nM for mouse intact proinsulin II and IC50 = 6.0 nM
for the 13-mer peptide). Mab-9F5 barely reacted with the
11-mer peptide or the 19-mer peptide, both of which lack the
31R–32R of the B–C junction (Fig. 2). The binding afﬁnity (KD) of
Mab-9F5 with mouse intact proinsulin II analyzed by a BIAcore
T200 system was 1.9 nM (Table 1). We conﬁrmed that Mab-9F5
reacted with mouse intact proinsulin I as well as mouse intact
proinsulin II (Fig. 3A) but not human intact proinsulin (data not
shown). These results demonstrated that the developed
anti-mouse proinsulin monoclonal antibody Mab-9F5 was speciﬁc
for the uncleaved B–C junction of mouse proinsulin.
A commercially available assay system for rodent intact
proinsulin has been lacking so far. We developed a sandwich
ELISA for the measurement of mouse intact proinsulin using
Mab-9F5 and an anti-mouse insulin B-chain monoclonal antibody
(Mab-13G4m1) established in our previous study [9]. The newly
developed ELISA displayed a wide range of standard curves for
mouse intact proinsulin (3.7–2700 pg/ml), with less than 1% of
cross-reactivity for split-32,33 proinsulin (the major intermediate
cleaved at the B–C junction) and no reactivity for mouse insulin
(Fig. 3), thereby suggesting high speciﬁcity for mouse intact proin-
sulin. Analytical validation of the developed ELISA using mouse
plasma samples demonstrated good dilutional linearity, good
recovery of spiked mouse intact proinsulin, and good reproducibil-
ity with intra- and inter-assay precision and accuracy (Fig. 4 and
Tables 2 and 3). The reproducibility assessment demonstrated that
the functional sensitivity of the developed ELISA using mouse
plasma was 8.3 to 1250 pg/ml, whereas the excellent precision
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Fig.5. Ratio of intact proinsulin/insulin in the plasma of type 2 diabetic db/db mice as a marker of disease progression. (A, B) Determination of plasma total proinsulin using a
commercially available Mouse/Rat Proinsulin ELISA (A) or of plasma intact proinsulin using the developed ELISA (B) was conducted with 10 blood samples in each group of 6-,
8-, and 9-week-old male db/db mice and 6-week-old male normal control littermate m/m mice. Plasma insulin and blood HbA1c are taken from Table 4. (C) Ratio of mouse
intact proinsulin/insulin. Data are the means ± SDs of 10 animals. **P < 0.01 versus normal control m/m mice; P < 0.01 versus 6-week-old db/db mice. (D) Scatter plot
between blood HbA1c (x-axis) and the ratio of intact proinsulin/insulin in plasma (y-axis). The Pearson’s correlation coefﬁcient between blood HbA1c and the ratio of intact
proinsulin/insulin was analyzed.
Speciﬁc mouse intact proinsulin ELISA / S. Imai et al. / Anal. Biochem. 484 (2015) 91–98 97(intra- and inter-assay CV values were <4.0%) indicated the possi-
bility to measure less than 8.3 pg/ml of intact proinsulin.
Besides body weight, plasma insulin, plasma glucose, and HbA1c
levels, plasma concentrations of intact proinsulin in control and
db/db mice were measured by the developed ELISA and compared
with that of total proinsulin determined by a commercially avail-
able ELISA. In parallel with the increases in HbA1c and plasma glu-
cose levels, plasma levels of intact proinsulin in db/db mice
increased progressively from 6 to 9 weeks of age (Fig. 5B), whereas
plasma total proinsulin levels reached a plateau in db/db mice at
6 weeks of age and did not increase anymore as mice aged
(Fig. 5A). The ratio of intact proinsulin/insulin in plasma of younger
db/db mice at 6 weeks of age was comparable to that of the
age-matched control mice (Fig. 5C), but the plasma insulin levels
were 20 times greater than those of the control mice (Table 4).
This observation suggested that proinsulin under accelerated pro-
duction could be processed efﬁciently to insulin in younger db/db
mice. Compared with the younger db/db mice at 6 weeks of age,
the ratio of intact proinsulin/insulin in plasma of db/db mice at
9 weeks of age was remarkably elevated. This phenomenon was
caused by continuous augmentation of intact proinsulin levels in
the plasma of db/db mice in parallel with a gradual decline in
plasma insulin levels. These results suggested that deteriorationof b-cell function in older db/db mice caused the release of greater
amounts of unprocessed proinsulin.
Features of intact proinsulin in the pathology of T2DM have
been reviewed by Pfutzner and Forst [15]. A minor percentage of
intact proinsulin is released into the circulation in healthy subjects,
and progressive resistance to insulin leads to an increased demand
for insulin. The persistence of enhanced production of insulin may
lead to exhaustion of the processing capacity of proinsulin, result-
ing in b-cell dysfunction. Patients with T2DM have exhibited eleva-
tion of circulating levels of intact proinsulin and, moreover,
elevation of the ratio of intact proinsulin/insulin in plasma due
to impaired processing of insulin in pancreatic b-cells [7].
Consistent with ﬁndings in humans, we observed that plasma
levels of intact proinsulin and the ratio of intact proinsulin/insulin
in plasma were signiﬁcantly increased in db/db mice as diabetic
disease progressed (Table 4 and Fig. 5B and C). In addition, the ratio
of intact proinsulin/insulin in plasma was signiﬁcantly correlated
with HbA1c levels (the ‘‘gold standard’’ for the diagnosis and mon-
itoring of T2DM) (Fig. 5D).
In conclusion, plasma intact proinsulin, but not plasma total
proinsulin, is likely to be a sensitive marker for monitoring func-
tion of pancreatic b-cells in db/db mice, and the ratio of intact
proinsulin/insulin in plasma could be a direct indicator of their
98 Speciﬁc mouse intact proinsulin ELISA / S. Imai et al. / Anal. Biochem. 484 (2015) 91–98impaired function, as it is in T2DM patients. The ELISA developed
in this study may be a useful tool for nonclinical evaluation of ther-
apeutic interventions in T2DM.
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